Biomarkers of anti-angiogenic therapy in breast cancer
<p>The hunt for biomarkers for anti-VEGF agent bevacizumab is ongoing since last decade with no success. Identifying robust biomarkers for stratifying patients and for monitoring response is important for the future use of bevacizumab in breast cancer. Dynamic contrast-enhanced magnetic resona...
Main Author: | Mehta, S |
---|---|
Other Authors: | Harris, A |
Format: | Thesis |
Language: | English |
Published: |
2014
|
Subjects: |
Similar Items
-
Combining regulatory angiogenic gene therapy and virotherapy for the treatment of breast cancer
by: Bazan Peregrino, M
Published: (2007) -
Investigating a role of HER3 in anti-HER2 target therapy in breast cancer
by: Hashimoto, K
Published: (2014) -
Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis
by: Knowles, H, et al.
Published: (2001) -
The role of StAR-D3 in HER2 overexpressing breast cancer
by: Mele, T
Published: (2012) -
Targeting EGFR signalling pathway in triple negative breast cancer
by: Albukhari, A
Published: (2014)